$MSOS - AdvisorShares Pure US Cannabis ETF Chart July 2022

AMEX:MSOS   AdvisorShares Trust AdvisorShares Pure US Cannabis ETF
AsvisorShares Pure US Cannabis ETF (MSOS) has been on a rampage and never shying away of selling off more than expecting, leaving pretty much the whole cannabis sector carrying the dead weight of a massive basket of synthetic weight, expelling a lot of investors and leaving the rest holding major bags from a short attach which started almost over 2 years ago now.

I believe we are on the last leg down on the current cycle and should see price action levels of $9.24 - $8.30 - $8.04 PT - As mentioned in prior published chart, I see 8/08 - 8/15 being pivotal dates that either will show signs of cycle correction that could lead into impulse or very may be an extension that continues to sell off (starts another 4-5 wave) for another setup around Nov. (which if that fails, rinse and repeat for Jan. and again in April...etc)

If the correction is to turn impulse right now, MSOS would need to close over $13.90 - $14.50, but unlikely event. After the 4th-5th leg down, if the cycle correction is present, there needs to be positive volume bids to close over $1140ish - $11.70(?) after our leg down. That should let the investor(s) know bull trap is likely broken and impulse will proceed. I remain cautious...

I see no let up or difference in the last two months of selling per vol profile. Each month prior averages 30M vol. and nearly 3 weeks of each month shows the volume reaching the 20 day average. The MACD on the daily appears to want to go north and grows closer to crossing the zero-line. But, is still far and below via weekly timeframe. The OBV doesn't show any weekly divergence, something to watch for when getting close to cycle correction.

The last two times I charted MSOS it each time if completely knifed and oversells on the 4th down into the 5th with some of the quickest bull traps, so let's see how this one plays out.


The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.